Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade

Anti-PD-1/PD-L1 therapy has achieved great success in the clinic; however, only a small fraction of cancer patient benefit from PD-1/PD-L1 blockade therapy, and overcoming resistance to PD-1/PD-L1 blockade has thus become a primary priority. In this study, we demonstrated that administration of PD-1...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncoimmunology
Päätekijät: Zha, Haoran, Han, Xiao, Zhu, Ying, Yang, Fei, Li, Yongsheng, Li, Qijing, Guo, Bo, Zhu, Bo
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis 2017
Aiheet:
Brief Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5665063/
https://ncbi.nlm.nih.gov/pubmed/29123963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1349587
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia